tickdelta
tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

JNJJohnson & Johnson

Health care · Pharmaceuticals · NYSE

Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. 10-K, Item 1

JNJ quote by TradingView
Headquarters
New Brunswick, NJ
CEO
Joaquin Duato
Next results
around Jan 20, 2027
Compare with peers → Embed
All key numbers (36, from the latest 10-K and 10-Q) From EDGAR
EPS (ttm)6.58Sales (ttm)99.3BNet income (ttm)16.1BSales growth+6.0%EPS growth+90.5%Sales Q/Q+5.9%
Free cash flow20.6BGross margin67.6%Oper. margin-Net margin16.2%FCF margin20.7%ROE19.7%
ROA8.2%R&D / sales0.1%Dividend5.14Debt/Eq0.55Curr. ratio1.02Cash16.9B
Op. cash flow (ttm)26.2BNet debt27.7BQuick ratio0.76Payout ratio46.6%Tax rate17.7%Stock pay / sales1.4%
Shares out.2.4BShares Y/Y0.0%Book / share33.87Cash / share7.02Sales / share41.26Asset turnover0.50
Inventory turns2.13Days sales out.67Sales 3Y CAGR+5.6%Sales 5Y CAGR+2.7%EPS 3Y CAGR+18.0%EPS 5Y CAGR+14.9%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Changes in the numbers

FY2025 against FY2024
  • Debt rose 30%$38.4B → $49.9B · Short-term + long-term debt at year end
What management wrote about it → · Every company →

JNJ against Health care peers

Ten years, side by side → · All 60 →
GrowthProfitBalanceCleanInsiders
JNJPeer median

Each side 0 to 100, ranked against every company we cover: relative position on reported figures, not a buy score. How

Every dot is one of the 60 companies, the better end on the right. Hover a dot for the company.

Sales growth
+6.0%36th of 60 · median +7.1%
Net margin
16.2%18th of 60 · median 9.6%
Return on equity
19.7%13th of 54 · median 13.1%
Free cash flow margin
20.7%17th of 56 · median 15.5%
Debt / equity (less is better)
0.5517th of 49 · median 0.66
JNJ and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthGross marginNet marginROEFCF marginDebt / equity
JNJ Johnson & Johnson$99.3B +6.0%67.6%16.2%19.7%20.7%0.55
LLY Eli Lilly$86.5B +44.7%83.6%31.9%68.5%-1.23
HCA HCA Healthcare$78.7B +7.1%-8.6%-7.6%-
MRK Merck & Co.$67.4B +1.3%71.8%3.6%5.5%21.9%1.20
ABBV AbbVie$66.0B +8.6%73.7%15.7%-28.6%-
PFE Pfizer$63.6B -1.6%73.4%6.3%4.5%18.5%0.70

From $78.7B of sales to $20.9B of profit

FY2021, from the 10-K income statement
Revenue to Gross profit: $55.3BRevenue to Cost of revenue: $23.4BGross profit to Net profit: $20.9BGross profit to Costs, tax, other: $34.5B Revenue: $78.7B Revenue$78.7B −5% Y/Y Gross profit: $55.3B · 70% margin Gross profit$55.3B70% margin +2% Y/Y Cost of revenue: $23.4B · 30% of revenue Cost of revenue$23.4B30% of revenue Net profit: $20.9B · 27% margin Net profit$20.9B27% margin +42% Y/Y Costs, tax, other: $34.5B · 44% of revenue Costs, tax, other$34.5B44% of revenue

Swipe sideways for the whole flow →

From $80.0B of sales to $17.9B of profit

FY2022, from the 10-K income statement and revenue by segment
Innovative Medicine to Revenue: $52.6BMedTech to Revenue: $27.4BRevenue to Gross profit: $55.4BRevenue to Cost of revenue: $24.6BGross profit to Net profit: $17.9BGross profit to Costs, tax, other: $37.5B Innovative Medicine: $52.6B · 66% Innovative Medicine$52.6B66% MedTech: $27.4B · 34% MedTech$27.4B34% Revenue: $80.0B Revenue$80.0B +2% Y/Y Gross profit: $55.4B · 69% margin Gross profit$55.4B69% margin +0% Y/Y Cost of revenue: $24.6B · 31% of revenue Cost of revenue$24.6B31% of revenue Net profit: $17.9B · 22% margin Net profit$17.9B22% margin −14% Y/Y Costs, tax, other: $37.5B · 47% of revenue Costs, tax, other$37.5B47% of revenue

Swipe sideways for the whole flow →

From $85.2B of sales to $35.2B of profit

FY2023, from the 10-K income statement and revenue by segment
Innovative Medicine to Revenue: $54.8BMedTech to Revenue: $30.4BRevenue to Gross profit: $58.6BRevenue to Cost of revenue: $26.6BGross profit to Net profit: $35.2BGross profit to Costs, tax, other: $23.5B Innovative Medicine: $54.8B · 64% Innovative Medicine$54.8B64% MedTech: $30.4B · 36% MedTech$30.4B36% Revenue: $85.2B Revenue$85.2B +6% Y/Y Gross profit: $58.6B · 69% margin Gross profit$58.6B69% margin +6% Y/Y Cost of revenue: $26.6B · 31% of revenue Cost of revenue$26.6B31% of revenue Net profit: $35.2B · 41% margin Net profit$35.2B41% margin +96% Y/Y Costs, tax, other: $23.5B · 28% of revenue Costs, tax, other$23.5B28% of revenue

Swipe sideways for the whole flow →

From $88.8B of sales to $14.1B of profit

FY2024, from the 10-K income statement and revenue by segment
Innovative Medicine to Revenue: $57.0BMedTech to Revenue: $31.9BRevenue to Gross profit: $61.4BRevenue to Cost of revenue: $27.5BGross profit to Net profit: $14.1BGross profit to Costs, tax, other: $47.3B Innovative Medicine: $57.0B · 64% Innovative Medicine$57.0B64% MedTech: $31.9B · 36% MedTech$31.9B36% Revenue: $88.8B Revenue$88.8B +4% Y/Y Gross profit: $61.4B · 69% margin Gross profit$61.4B69% margin +5% Y/Y Cost of revenue: $27.5B · 31% of revenue Cost of revenue$27.5B31% of revenue Net profit: $14.1B · 16% margin Net profit$14.1B16% margin −60% Y/Y Costs, tax, other: $47.3B · 53% of revenue Costs, tax, other$47.3B53% of revenue

Swipe sideways for the whole flow →

From $94.2B of sales to $26.8B of profit

FY2025, from the 10-K income statement and revenue by segment
Innovative Medicine to Revenue: $60.4BMedTech to Revenue: $33.8BRevenue to Gross profit: $63.9BRevenue to Cost of revenue: $30.3BGross profit to Net profit: $26.8BGross profit to Costs, tax, other: $37.1B Innovative Medicine: $60.4B · 64% Innovative Medicine$60.4B64% MedTech: $33.8B · 36% MedTech$33.8B36% Revenue: $94.2B Revenue$94.2B +6% Y/Y Gross profit: $63.9B · 68% margin Gross profit$63.9B68% margin +4% Y/Y Cost of revenue: $30.3B · 32% of revenue Cost of revenue$30.3B32% of revenue Net profit: $26.8B · 28% margin Net profit$26.8B28% margin +91% Y/Y Costs, tax, other: $37.1B · 39% of revenue Costs, tax, other$37.1B39% of revenue

Swipe sideways for the whole flow →

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • Costs, tax, other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement →

Profitability

4 of 4
  • ✓
    Net margin above the peer median16.2% vs 9.6%
  • ✓
    Gross margin up over 5 years65.6% → 67.9%
  • ✓
    Return on equity above 15%19.7%
  • ✓
    A profit in every one of 10 years
Net margin, FY2016 to FY2025: 23.0% → 28.5%

Balance sheet

3 of 3
  • ✓
    Debt smaller than equityDebt / equity 0.55 on the latest balance sheet (peer median 0.66)
  • ✓
    Current assets cover current liabilitiesCurrent ratio 1.02
  • ✓
    Net debt under 3 years of free cash flow$27.3B net debt, 1.3 years
Debt / equity at each year end, FY2016 to FY2025: 0.41 → 0.61
What the debt is made of ↓

Cash and shareholders

3 of 4
  • ✓
    Free cash flow positive in every one of 10 years$19.7B last year
  • ✓
    Share count down over 5 years−9.0%
  • ✓
    Dividend per share up over 5 years$3.98 → $5.14
  • !
    Cash from operations below net income$24.5B vs $26.8B
Free cash flow, FY2016 to FY2025: 15.5B → 19.7B

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

What the debt is made of, and when it is due

balance sheet of Sep 27, 2026 · schedule of Dec 28, 2025
Debt: $44.7B Debt$44.7B Long-term debt: $35.8B · 77% Long-term debt$35.8B · 77% Due within a year: $2.0B · 4% Due within a year$2.0B · 4% Short-term borrowings: $8.9B · 19% Short-term borrowings$8.9B · 19% Next 12 months: $2.0B · 4% Next 12 months$2.0B · 4% Year 2: $3.2B · 7% Year 2$3.2B · 7% Year 3: $3.1B · 7% Year 3$3.1B · 7% Year 4: $2.2B · 5% Year 4$2.2B · 5% Year 5: $2.7B · 6% Year 5$2.7B · 6% After year 5: $28.3B · 61% After year 5$28.3B · 61%

The debt note's own lines, 2025-12-28

Fixed rate $0Floating $6.5B Not stated $41.4B

Line, as the company names itKindRateFixed or floatingAmount
Commercial PaperCommercial paper–floating$6.5B
2.45% Notes due 2026Notes and bonds2.45%not stated$2.0B
3.73% Notes due 2046Notes and bonds3.73%not stated$2.0B
1.650% Notes Due May 2035Notes and bonds1.65%not stated$1.8B
1.30% Notes due 2030Notes and bonds1.30%not stated$1.7B
0.95% Notes due 2027Notes and bonds0.95%not stated$1.5B
2.90% Notes due 2028Notes and bonds2.90%not stated$1.5B
3.625% Notes due 2037Notes and bonds3.62%not stated$1.4B
5.00% Notes Due 2035Notes and bonds5.00%not stated$1.2B
4.85% Notes due 2032Notes and bonds4.85%not stated$1.2B
3.35% Notes due 2037Notes and bonds3.35%not stated$1.2B
3.70% Notes due 2055Notes and bonds3.70%not stated$1.2B
3.55% Notes due 2044Notes and bonds3.55%not stated$1.2B
4.80% Notes due 2029Notes and bonds4.80%not stated$1.1B
4.90% Notes due 2031Notes and bonds4.90%not stated$1.1B
2.45% Notes due 2060Notes and bonds2.45%not stated$1.1B
4.70% Notes due 2030Notes and bonds4.70%not stated$996.0M
5.95% Notes due 2037Notes and bonds5.95%not stated$995.0M
3.40% Notes due 2038Notes and bonds3.40%not stated$994.0M
2.95% Notes due 2027Notes and bonds2.95%not stated$968.0M
3.35% Notes due 2036Notes and bonds3.35%not stated$938.0M
3.587% Notes due 2036Notes and bonds3.59%not stated$919.0M
2.10% Notes due 2040Notes and bonds2.10%not stated$898.0M
1.150% Notes Due November 2028Notes and bonds1.15%not stated$882.0M
3.75% Notes due 2047Notes and bonds3.75%not stated$876.0M
2.25% Notes due 2050Notes and bonds2.25%not stated$861.0M
4.375% Notes due 2033Notes and bonds4.38%not stated$853.0M
4.95% Notes due 2034Notes and bonds4.95%not stated$847.0M
5.25% Notes due 2054Notes and bonds5.25%not stated$843.0M
3.05% Notes due 2033Notes and bonds–not stated$823.0M
3.20% Notes due 2032Notes and bonds3.20%not stated$822.0M
3.60% Notes due 2045Notes and bonds3.60%not stated$819.0M
4.50% Notes due 2027Notes and bonds4.50%not stated$749.0M
4.55% Notes Due 2028Notes and bonds4.55%not stated$748.0M
3.50% Notes due 2048Notes and bonds3.50%not stated$744.0M
2.700% Notes Due 2029Notes and bonds2.70%not stated$707.0M
5.85% Notes due 2038Notes and bonds5.85%not stated$697.0M
4.50% Notes due 2040Notes and bonds4.50%not stated$542.0M
4.95% Notes due 2033Notes and bonds4.95%not stated$499.0M
4.50% Notes due 2043Notes and bonds4.50%not stated$497.0M
6.95% Notes due 2029Notes and bonds6.95%not stated$299.0M
4.85% Notes due 2041Notes and bonds4.85%not stated$298.0M
Other––not stated$79.0M
All 43 lines

From the debt note in the 10-K's XBRL (0000200406-26-000016), as the company tags it: by issue, by year, by currency or by kind. Lines from two ways of cutting the same debt can overlap, so they are not added up. Fixed or floating is read from the line's own name only; "not stated" when it says neither.

Left: the debt lines on the balance sheet (XBRL). Right: the principal due each year, from the debt note's maturity schedule; it can differ a little from the balance sheet, which shows the debt net of discounts and fees. Leases are not counted. The full schedule →

Revenue and net income, FY2016 to FY2025

Revenue 94.2B Net income 26.8B
FY2016 revenue 71.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000200406-19-000009 FY2016 net income 16.5B · NetIncomeLoss, 0000200406-19-000009 71.9B FY2016 FY2017 revenue 76.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000200406-20-000010 FY2017 net income 1.3B · NetIncomeLoss, 0000200406-20-000010 76.5B FY2017 FY2018 revenue 81.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000200406-21-000008 FY2018 net income 15.3B · NetIncomeLoss, 0000200406-21-000008 81.6B FY2018 FY2019 revenue 82.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000200406-22-000022 FY2019 net income 15.1B · NetIncomeLoss, 0000200406-22-000022 82.1B FY2019 FY2021 revenue 82.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000200406-23-000016 FY2021 net income 14.7B · NetIncomeLoss, 0000200406-23-000016 82.6B FY2021 FY2021 revenue 78.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000200406-24-000013 FY2021 net income 20.9B · NetIncomeLoss, 0000200406-24-000013 78.7B FY2021 FY2022 revenue 80.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000200406-25-000038 FY2022 net income 17.9B · NetIncomeLoss, 0000200406-25-000038 80.0B FY2022 FY2023 revenue 85.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000200406-26-000016 FY2023 net income 35.2B · NetIncomeLoss, 0000200406-26-000016 85.2B FY2023 FY2024 revenue 88.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000200406-26-000016 FY2024 net income 14.1B · NetIncomeLoss, 0000200406-26-000016 88.8B FY2024 FY2025 revenue 94.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000200406-26-000016 FY2025 net income 26.8B · NetIncomeLoss, 0000200406-26-000016 94.2B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. Full financials →

JNJ's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Annual Quarterly
Revenue94.2B
FY2016: 71.9BFY2017: 76.5BFY2018: 81.6BFY2019: 82.1BFY2021: 82.6BFY2021: 78.7BFY2022: 80.0BFY2023: 85.2BFY2024: 88.8BFY2025: 94.2B FY2017FY2019FY2021FY2023FY2025
Net income26.8B
FY2016: 16.5BFY2017: 1.3BFY2018: 15.3BFY2019: 15.1BFY2021: 14.7BFY2021: 20.9BFY2022: 17.9BFY2023: 35.2BFY2024: 14.1BFY2025: 26.8B FY2017FY2019FY2021FY2023FY2025
Free cash flow19.7B
FY2016: 15.5BFY2017: 17.8BFY2018: 18.5BFY2019: 19.9BFY2021: 20.2BFY2021: 19.8BFY2022: 17.2BFY2023: 18.2BFY2024: 19.8BFY2025: 19.7B FY2017FY2019FY2021FY2023FY2025
EPS (diluted)11.03
FY2016: 5.93FY2017: 0.47FY2018: 5.61FY2019: 5.63FY2021: 5.51FY2021: 7.81FY2022: 6.73FY2023: 13.72FY2024: 5.79FY2025: 11.03 FY2017FY2019FY2021FY2023FY2025
Dividend per share5.14
FY2016: 3.15FY2017: 3.32FY2018: 3.54FY2019: 3.75FY2021: 3.98FY2021: 4.19FY2022: 4.45FY2023: 4.70FY2024: 4.91FY2025: 5.14 FY2017FY2019FY2021FY2023FY2025
Diluted shares2.4B
FY2016: 2.8BFY2017: 2.7BFY2018: 2.7BFY2019: 2.7BFY2021: 2.7BFY2021: 2.7BFY2022: 2.7BFY2023: 2.6BFY2024: 2.4BFY2025: 2.4B FY2017FY2019FY2021FY2023FY2025

Revenue by business segment

year to Dec 28, 2025
RevenueSharevs year before
Innovative Medicine 60.4B64.1% +6.0%
MedTech 33.8B35.9% +6.1%

10-K 0000200406-26-000016, segment and revenue notes (XBRL).

Revenue by region

year to Dec 28, 2025
RevenueSharevs year before
U.S. Plans 53.8B57.1% +6.9%
Non-US 40.4B42.9% +5.0%
Europe 21.5B22.9% +6.5%
Asia Pacific Africa 14.0B14.9% +3.2%
Western Hemisphere Excluding US 4.9B5.2% +3.4%

10-K 0000200406-26-000016, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2021FY2021FY2022FY2023FY2024FY2025
Revenue71.9B76.5B81.6B82.1B82.6B78.7B80.0B85.2B88.8B94.2B
Cost of revenue21.8B25.4B27.1B27.6B28.4B23.4B24.6B26.6B27.5B30.3B
Gross profit50.1B51.0B54.5B54.5B54.2B55.3B55.4B58.6B61.4B63.9B
R&D9.1B10.6B10.8B11.4B12.2B00483.0M1.8B109.0M
SG&A20.1B21.5B22.5B22.2B22.1B20.1B20.2B21.5B22.9B23.7B
Interest expense726.0M934.0M1.0B318.0M201.0M183.0M276.0M772.0M755.0M971.0M
Pretax income19.8B17.7B18.0B17.3B16.5B19.2B19.4B15.1B16.7B32.6B
Income tax3.3B16.4B2.7B2.2B1.8B1.4B3.0B1.7B2.6B5.8B
Net income16.5B1.3B15.3B15.1B14.7B20.9B17.9B35.2B14.1B26.8B
EPS (diluted)5.930.475.615.635.517.816.7313.725.7911.03
Diluted shares2.8B2.7B2.7B2.7B2.7B2.7B2.7B2.6B2.4B2.4B
Depreciation & amortization3.8B5.6B6.9B7.0B7.2B7.4B7.0B7.5B7.3B7.5B
Gross margin69.7%66.7%66.8%66.4%65.6%70.3%69.3%68.8%69.1%67.9%
Net margin23.0%1.7%18.8%18.4%17.8%26.5%22.4%41.3%15.8%28.5%
Revenue growth-+6.3%+6.7%+0.6%+0.6%-4.7%+1.6%+6.5%+4.3%+6.0%
EPS growth--92.1%+1094%+0.4%-2.1%+41.7%-13.8%+104%-57.8%+90.5%

Balance sheet

From EDGAR
FY2016FY2017FY2018FY2019FY2021FY2021FY2022FY2023FY2024FY2025
Cash19.0B17.8B18.1B17.3B14.0B14.5B12.9B21.9B24.1B19.7B
Short-term investments22.9B472.0M1.6B2.0B11.2B17.1B9.4B1.1B417.0M393.0M
Receivables11.7B13.5B14.1B14.5B13.6B15.3B14.0B14.9B14.8B17.2B
Inventory8.1B8.8B8.6B9.0B9.3B10.4B10.3B11.2B12.4B14.2B
Current assets65.0B43.1B46.0B45.3B51.2B61.0B55.3B53.5B55.9B55.6B
Property & equipment15.9B17.0B17.0B17.7B18.8B19.0B18.0B19.9B20.5B23.2B
Goodwill22.8B31.9B30.5B33.6B36.4B25.4B36.0B36.6B44.2B48.8B
Total assets141.2B157.3B153.0B157.7B174.9B182.0B187.4B167.6B180.1B199.2B
Accounts payable6.9B7.3B7.5B8.5B9.5B11.1B9.9B9.6B10.3B12.0B
Current liabilities26.3B30.5B31.2B36.0B42.5B45.2B55.8B46.3B50.3B54.1B
Total debt28.8B36.1B33.1B27.7B37.1B35.9B41.2B30.8B38.4B49.9B
Total liabilities70.8B97.1B93.2B98.3B111.6B108.0B110.6B98.8B108.6B117.7B
Shareholders' equity70.4B60.2B59.8B59.5B63.3B74.0B76.8B68.8B71.5B81.5B
Retained earnings110.6B101.8B106.2B110.7B113.9B123.1B128.3B153.8B155.8B169.0B

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2021FY2021FY2022FY2023FY2024FY2025
Operating cash flow18.8B21.1B22.2B23.4B23.5B23.4B21.2B22.8B24.3B24.5B
Capital spending3.2B3.3B3.7B3.5B3.3B3.7B4.0B4.5B4.4B4.8B
Free cash flow15.5B17.8B18.5B19.9B20.2B19.8B17.2B18.2B19.8B19.7B
Stock-based pay (added back)878.0M962.0M978.0M977.0M1.0B1.1B1.1B1.2B1.2B1.4B
Buybacks9.0B6.4B5.9B6.7B3.2B3.5B6.0B5.1B2.4B6.0B
Acquisitions4.5B35.2B899.0M5.8B7.3B60.0M17.7B015.1B17.5B
Debt raised12.0B9.0B5.0M3.0M7.4B5.0M2.0M06.7B9.1B
Debt repaid2.2B1.8B1.6B2.8B1.1B1.8B2.1B1.6B1.5B1.8B
Investing cash flow-4.8B-14.9B-3.2B-6.2B-20.8B-8.7B-12.4B878.0M-18.6B-23.6B
Financing cash flow-8.6B-7.7B-18.5B-18.0B-6.1B-14.0B-8.9B-15.8B-3.1B-5.5B
Dividend per share3.153.323.543.753.984.194.454.704.915.14

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2021FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)878.0M962.0M978.0M977.0M1.0B1.1B1.1B1.2B1.2B1.4B
Stock-based pay / revenue1.2%1.3%1.2%1.2%1.2%1.4%1.4%1.4%1.3%1.4%
Operating lease cost-372.0M300.0M300.0M300.0M200.0M200.0M200.0M200.0M200.0M
Operating lease cash paid---300.0M300.0M200.0M200.0M200.0M200.0M300.0M
Right-of-use assets---1.0B1.0B900.0M1.1B1.0B1.1B1.3B
Operating lease liabilities---1.0B1.1B1.0B1.3B1.1B1.2B1.4B

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Work on JNJ in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/JNJ/export.csv") into a cell.